Compare Enbridge Inc (ENB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs GeneDx Holdings Corp — how do they compare? Enbridge Inc trades at $56.23 (market cap $121.39B), while GeneDx Holdings Corp trades at $61.39 (market cap $1.96B). The key difference: Enbridge Inc is far larger — about 61.9× GeneDx Holdings Corp's market cap, and Enbridge Inc pays a 5.01% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| ENB | WGS | |
|---|---|---|
Market Cap | $121.39B | $1.96B |
Sector | Energy | Technology |
52-Week High | $58.04 | $167.51 |
52-Week Low | $44.59 | $34.51 |
Enterprise Value | $202.19B | $1.96B |
Dividend Yield | 5.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $56.20, up 0.55% with a bullish technical outlook. Recent earnings show mixed results with Q1 2026 beating estimates but Q3 2025 missing. The company maintains strong cash flow from operations of $12.27B in 2025 and a 5.1% dividend yield. Revenue grew to $65.19B in 2025, with net income margin at 10%. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook remains positive due to $28B in growth projects and stable dividends, but risks include high debt levels (debt-to-asset ratio 48.81% in 2025) and sensitivity to energy market volatility. The stock offers income appeal but faces execution risks on capital expenditures.
WGS trades at $62.73, up 0.48% on the day, amid a bearish technical signal and negative earnings momentum. The stock faces significant headwinds from a class action lawsuit alleging securities fraud tied to a 49% stock decline, while fundamentals show a net loss of $21.02 million in 2025 and deteriorating profitability into 2026. Analyst consensus remains bullish with a $75.40 price target, but recent news flow is overwhelmingly negative.
The outlook is clouded by legal risks and weak financial performance, though analyst optimism suggests potential recovery if the company can stabilize operations. Key risks include litigation outcomes, execution on profitability, and market sentiment shifts. The stock's trajectory hinges on resolving legal challenges and demonstrating sustainable earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
